

Mehmet Sofuoglu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11672135/publications.pdf>

Version: 2024-02-01

136
papers

6,332
citations

50276

46
h-index

76900

74
g-index

136
all docs

136
docs citations

136
times ranked

5551
citing authors

#	ARTICLE	IF	CITATIONS
1	Reappraising Choice in Addiction: Novel Conceptualizations and Treatments for Tobacco Use Disorder. <i>Nicotine and Tobacco Research</i> , 2022, 24, 3-9.	2.6	14
2	Impact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science. <i>Addiction Biology</i> , 2022, 27, e13161.	2.6	3
3	Plasma Menthol Glucuronide as a Biomarker for the Behavioral Effects of Menthol and Nicotine in Humans. <i>Frontiers in Pharmacology</i> , 2022, 13, 844824.	3.5	0
4	Development of pulsed intravenous nicotine infusions as a model for inhaled nicotine in humans. <i>Psychopharmacology</i> , 2022, 239, 2809-2818.	3.1	0
5	Progesterone Increases Nicotine Withdrawal and Anxiety in Male but Not Female Smokers During Brief Abstinence. <i>Nicotine and Tobacco Research</i> , 2022, 24, 1898-1905.	2.6	3
6	Sex Differences in Opioid Use Disorder Prevalence and Multimorbidity Nationally in the Veterans Health Administration. <i>Journal of Dual Diagnosis</i> , 2021, 17, 124-134.	1.2	11
7	Threshold dose for intravenous nicotine self-administration in young adult non-dependent smokers. <i>Psychopharmacology</i> , 2021, 238, 2083-2090.	3.1	6
8	Baseline executive functions and receiving cognitive rehabilitation can predict treatment response in people with opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108558.	2.8	7
9	Treatment outcomes in individuals diagnosed with comorbid opioid use disorder and Posttraumatic stress disorder: A review. <i>Addictive Behaviors</i> , 2021, 122, 107026.	3.0	6
10	Acute effects of inhaled menthol on cognitive effects of intravenous nicotine among young adult cigarette smokers. <i>Addictive Behaviors</i> , 2021, 122, 107022.	3.0	1
11	Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109097.	3.2	9
12	Modulation of "Protective" Nicotine Perception and Use Profile by Flavorants: Preliminary Findings in E-cigarettes. <i>Nicotine and Tobacco Research</i> , 2020, 22, 771-781.	2.6	26
13	Pharmacological cognitive enhancers. , 2020, , 303-320.		1
14	Impact of cannabis on non-medical opioid use and symptoms of posttraumatic stress disorder: a nationwide longitudinal VA study. <i>American Journal of Drug and Alcohol Abuse</i> , 2020, 46, 812-822.	2.1	4
15	Naturalistic measurement of dual cue attentional bias in moderate to heavy-drinking smokers: A preliminary investigation. <i>Drug and Alcohol Dependence</i> , 2020, 209, 107892.	3.2	5
16	Differential effects of nicotine delivery rate on subjective drug effects, urges to smoke, heart rate and blood pressure in tobacco smokers. <i>Psychopharmacology</i> , 2020, 237, 1359-1369.	3.1	10
17	Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder. <i>Journal of Substance Abuse Treatment</i> , 2019, 107, 29-37.	2.8	14
18	Anhedonia as a Key Clinical Feature in the Maintenance and Treatment of Opioid Use Disorder. <i>Clinical Psychological Science</i> , 2019, 7, 1190-1206.	4.0	36

#	ARTICLE	IF	CITATIONS
19	Pharmacological and Behavioral Treatment of Opioid Use Disorder. <i>Psychiatric Research and Clinical Practice</i> , 2019, 1, 4-15.	2.4	53
20	Adverse Consequences of Co-Occurring Opioid Use Disorder and Cannabis Use Disorder Compared to Opioid Use Disorder Only. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 527-537.	2.1	14
21	The Opioid Crisis: Filling in the Picture. <i>Psychiatric Research and Clinical Practice</i> , 2019, 1, 2-3.	2.4	0
22	Double-Blind Placebo-Controlled Trial of Galantamine for Methadone-Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. <i>American Journal on Addictions</i> , 2019, 28, 238-245.	1.4	13
23	Stress and opioid use disorder: A systematic review. <i>Addictive Behaviors</i> , 2019, 98, 106010.	3.0	24
24	Feasibility and effects of galantamine on cognition in humans with cannabis use disorder. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 181, 86-92.	2.9	10
25	Targeting neuroinflammation with minocycline in heavy drinkers. <i>Psychopharmacology</i> , 2019, 236, 3013-3021.	3.1	20
26	E-cigarette nicotine dose and flavor: Relationship with appeal, choice, and tobacco use amongst veterans with comorbid psychiatric disorders. <i>Addictive Behaviors</i> , 2019, 92, 53-57.	3.0	9
27	Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients. <i>Psychopharmacology</i> , 2019, 236, 2857-2866.	3.1	25
28	E-cigarettes, alcohol use, and mental health: Use and perceptions of e-cigarettes among college students, by alcohol use and mental health status. <i>Addictive Behaviors</i> , 2019, 91, 12-20.	3.0	50
29	Cognitive rehabilitation for individuals with opioid use disorder: A randomized controlled trial. <i>Neuropsychological Rehabilitation</i> , 2019, 29, 1273-1289.	1.6	32
30	Gender Differences in the Prevalence of Fibromyalgia and in Concomitant Medical and Psychiatric Disorders: A National Veterans Health Administration Study. <i>Journal of Women's Health</i> , 2018, 27, 1035-1044.	3.3	57
31	Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial. <i>Drug and Alcohol Dependence</i> , 2018, 186, 130-137.	3.2	6
32	Impact of E-cigarettes on Smoking and Related Outcomes in Veteran Smokers With Psychiatric Comorbidity. <i>Journal of Dual Diagnosis</i> , 2018, 14, 2-13.	1.2	19
33	Tobacco and alcohol use disorders: Evaluating multimorbidity. <i>Addictive Behaviors</i> , 2018, 78, 59-66.	3.0	33
34	The Cholinergic System as a Treatment Target for Opioid Use Disorder. <i>CNS Drugs</i> , 2018, 32, 981-996.	5.9	22
35	Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2018, 192, 264-270.	3.2	62
36	Attentional bias in opioid users: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2018, 191, 270-278.	3.2	30

#	ARTICLE	IF	CITATIONS
37	Acute effects of inhaled menthol on the rewarding effects of intravenous nicotine in smokers. <i>Journal of Psychopharmacology</i> , 2018, 32, 986-994.	4.0	13
38	Role of Exogenous Progesterone in the Treatment of Men and Women with Substance Use Disorders: A Narrative Review. <i>CNS Drugs</i> , 2018, 32, 421-435.	5.9	26
39	Stimulants and Mood Disorders. <i>Current Addiction Reports</i> , 2018, 5, 323-329.	3.4	2
40	Effects of galantamine on smoking behavior and cognitive performance in treatment-seeking smokers prior to a quit attempt. <i>Human Psychopharmacology</i> , 2018, 33, e2665.	1.5	11
41	Biochemical, demographic, and self-reported tobacco-related predictors of the acute heart rate response to nicotine in smokers. <i>Pharmacology Biochemistry and Behavior</i> , 2018, 173, 36-43.	2.9	6
42	Cognitive Effects of Nicotine: Recent Progress. <i>Current Neuropharmacology</i> , 2018, 16, 403-414.	2.9	137
43	Galantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 17m11669.	2.2	44
44	Pharmacological treatments for methamphetamine addiction: current status and future directions. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1-10.	3.1	63
45	Exclusion of participants based on substance use status: Findings from randomized controlled trials of treatments for PTSD. <i>Behaviour Research and Therapy</i> , 2017, 89, 33-40.	3.1	27
46	Inhalation of Alcohol Vapor: Measurement and Implications. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 238-250.	2.4	41
47	Rates and Correlates of Pain Specialty Clinic Use Nationally in the Veterans Health Administration. <i>Pain Medicine</i> , 2017, 18, pnw206.	1.9	15
48	Neurocognitive Function as a Treatment Target for Tobacco Use Disorder. <i>Current Behavioral Neuroscience Reports</i> , 2017, 4, 10-20.	1.3	8
49	Carvedilol does not reduce cocaine use in methadone-maintained cocaine users. <i>Journal of Substance Abuse Treatment</i> , 2017, 73, 63-69.	2.8	5
50	Atomoxetine in abstinent cocaine users: Sex differences. <i>Data in Brief</i> , 2017, 14, 566-572.	1.0	3
51	Progesterone for smoking relapse prevention following delivery: A pilot, randomized, double-blind study. <i>Psychoneuroendocrinology</i> , 2017, 86, 96-103.	2.7	22
52	Receptivity to a peer counselling program and recovery atmosphere as perceived by Veterans Health Administration peer support specialists and supervisors. <i>American Journal of Psychiatric Rehabilitation</i> , 2017, 20, 62-73.	0.7	2
53	Atomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects. <i>Pharmacology Biochemistry and Behavior</i> , 2017, 159, 55-61.	2.9	9
54	Effect of Menthol-preferring Status on Response to Intravenous Nicotine. <i>Tobacco Regulatory Science (discontinued)</i> , 2016, 2, 317-328.	0.2	12

#	ARTICLE	IF	CITATIONS
55	How Intravenous Nicotine Administration in Smokers Can Inform Tobacco Regulatory Science. Tobacco Regulatory Science (discontinued), 2016, 2, 452-463.	0.2	7
56	Toward Refinement of Our Understanding of the Fundamental Nature of Addiction. Biological Psychiatry, 2016, 80, 172-173.	1.3	5
57	Stress response genes and the severity of nicotine withdrawal. Pharmacogenomics, 2016, 17, 1-3.	1.3	7
58	Comparisons of Cocaine-Only, Opioid-Only, and Users of Both Substances in the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Substance Use and Misuse, 2016, 51, 553-564.	1.4	21
59	Intravenous Nicotine Self-Administration in Smokers: Dose-Response Function and Sex Differences. Neuropsychopharmacology, 2016, 41, 2034-2040.	5.4	29
60	Cognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders. Journal of Dual Diagnosis, 2016, 12, 90-106.	1.2	78
61	Perspectives on neurocognitive rehabilitation as an adjunct treatment for addictive disorders. Progress in Brain Research, 2016, 224, 345-369.	1.4	50
62	Effects of progesterone stimulated allopregnanolone on craving and stress response in cocaine dependent men and women. Psychoneuroendocrinology, 2016, 65, 44-53.	2.7	58
63	The effects of alcohol-containing e-cigarettes on young adult smokers. Drug and Alcohol Dependence, 2016, 159, 272-276.	3.2	33
64	Prevalence and correlates of coprescribing anxiolytic medications with extensive prescription opioid use in Veterans Health Administration patients with metastatic cancer. Journal of Opioid Management, 2016, 12, 259-268.	0.5	4
65	Catechol-O-methyltransferase gene Val158met polymorphism as a potential predictor of response to computer-assisted delivery of cognitive-behavioral therapy among cocaine-dependent individuals: Preliminary findings from a randomized controlled trial. American Journal on Addictions, 2015, 24, 443-451.	1.4	6
66	A CHRNA5 Smoking Risk Variant Decreases the Aversive Effects of Nicotine in Humans. Neuropsychopharmacology, 2015, 40, 2813-2821.	5.4	64
67	Prevalence and correlates of co-prescribing psychotropic medications with long-term opioid use nationally in the Veterans Health Administration. Psychiatry Research, 2015, 227, 324-332.	3.3	27
68	Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals. Journal of Psychopharmacology, 2015, 29, 312-323.	4.0	26
69	A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessation. Journal of Psychopharmacology, 2015, 29, 300-311.	4.0	66
70	NEuro COgnitive REhabilitation for Disease of Addiction (NECOREDA) Program: From Development to Trial. Basic and Clinical Neuroscience, 2015, 6, 291-8.	0.6	16
71	Subjective, Physiological, and Cognitive Responses to Intravenous Nicotine: Effects of Sex and Menstrual Cycle Phase. Neuropsychopharmacology, 2014, 39, 1431-1440.	5.4	73
72	Effects of endogenous and exogenous progesterone on emotional intelligence in cocaine-dependent men and women who also abuse alcohol. Human Psychopharmacology, 2014, 29, 589-598.	1.5	18

#	ARTICLE	IF	CITATIONS
73	Future pharmacological treatments for substance use disorders. British Journal of Clinical Pharmacology, 2014, 77, 382-400.	2.4	48
74	Progesterone for the reduction of cocaine use in post-partum women with a cocaine use disorder: a randomised, double-blind, placebo-controlled, pilot study. Lancet Psychiatry, the, 2014, 1, 360-367.	7.4	40
75	Pharmacological treatment of comorbid PTSD and substance use disorder: Recent progress. Addictive Behaviors, 2014, 39, 428-433.	3.0	52
76	A critical review of the literature on attentional bias in cocaine use disorder and suggestions for future research.. Experimental and Clinical Psychopharmacology, 2014, 22, 469-483.	1.8	60
77	The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology, 2013, 227, 177-192.	3.1	165
78	The effects of exogenous progesterone on drug craving and stress arousal in cocaine dependence: Impact of gender and cue type. Psychoneuroendocrinology, 2013, 38, 1532-1544.	2.7	124
79	Cognitive enhancement as a treatment for drug addictions. Neuropharmacology, 2013, 64, 452-463.	4.1	251
80	Rapid Nicotine Clearance is Associated with Greater Reward and Heart Rate Increases from Intravenous Nicotine. Neuropsychopharmacology, 2012, 37, 1509-1516.	5.4	98
81	The reinforcement threshold for nicotine as a target for tobacco control. Drug and Alcohol Dependence, 2012, 125, 1-7.	3.2	32
82	Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report. Psychopharmacology, 2012, 224, 413-420.	3.1	28
83	Commentary on Ling & Foltz (2012): The PROMETA treatment does not reduce methamphetamine use. Addiction, 2012, 107, 370-371.	3.3	0
84	Neuroscience of Behavioral and Pharmacological Treatments for Addictions. Neuron, 2011, 69, 695-712.	8.1	188
85	Galantamine improves sustained attention in chronic cocaine users.. Experimental and Clinical Psychopharmacology, 2011, 19, 11-19.	1.8	37
86	Effects of Galantamine on Cocaine Use in Chronic Cocaine Users. American Journal on Addictions, 2011, 20, 302-303.	1.4	24
87	Progesterone improves cognitive performance and attenuates smoking urges in abstinent smokers. Psychoneuroendocrinology, 2011, 36, 123-132.	2.7	65
88	Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans. Psychopharmacology, 2011, 213, 61-68.	3.1	55
89	Stress decreases the ability to resist smoking and potentiates smoking intensity and reward. Journal of Psychopharmacology, 2011, 25, 490-502.	4.0	227
90	Cognitive function as an emerging treatment target for marijuana addiction.. Experimental and Clinical Psychopharmacology, 2010, 18, 109-119.	1.8	57

#	ARTICLE	IF	CITATIONS
91	Role of progesterone in nicotine addiction: Evidence from initiation to relapse.. <i>Experimental and Clinical Psychopharmacology</i> , 2010, 18, 451-461.	1.8	140
92	Cognitive enhancement as a pharmacotherapy target for stimulant addiction. <i>Addiction</i> , 2010, 105, 38-48.	3.3	145
93	The Impact of Cigarette Smoking on Stimulant Addiction. <i>American Journal of Drug and Alcohol Abuse</i> , 2009, 35, 12-17.	2.1	98
94	Atomoxetine Attenuates Dextroamphetamine Effects in Humans. <i>American Journal of Drug and Alcohol Abuse</i> , 2009, 35, 412-416.	2.1	31
95	Minocycline reduced craving for cigarettes but did not affect smoking or intravenous nicotine responses in humans. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 92, 135-140.	2.9	31
96	Progesterone effects on subjective and physiological responses to intravenous nicotine in male and female smokers. <i>Human Psychopharmacology</i> , 2009, 24, 559-564.	1.5	56
97	Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. <i>Psychopharmacology</i> , 2009, 207, 153-162.	3.1	27
98	REVIEW: Norepinephrine and stimulant addiction. <i>Addiction Biology</i> , 2009, 14, 119-129.	2.6	170
99	The Effect of Cannabis Compared with Alcohol on Driving. <i>American Journal on Addictions</i> , 2009, 18, 185-193.	1.4	272
100	Cholinergic Functioning in Stimulant Addiction. <i>CNS Drugs</i> , 2009, 23, 939-952.	5.9	61
101	Subjective responses to intravenous nicotine: Greater sensitivity in women than in men.. <i>Experimental and Clinical Psychopharmacology</i> , 2009, 17, 63-69.	1.8	42
102	Modafinil and nicotine interactions in abstinent smokers. <i>Human Psychopharmacology</i> , 2008, 23, 21-30.	1.5	17
103	Disulfiram enhances subjective effects of dextroamphetamine in humans. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 90, 394-398.	2.9	16
104	Riluzole and d-amphetamine interactions in humans. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 16-22.	4.8	21
105	Reply: Response to Letter to the Editor. <i>Neuropsychopharmacology</i> , 2008, 33, 2044-2044.	5.4	0
106	Self-Administration of Intravenous Nicotine in Male and Female Cigarette Smokers. <i>Neuropsychopharmacology</i> , 2008, 33, 715-720.	5.4	55
107	Treatment Outcome Predictors for Cocaine Dependence. <i>American Journal of Drug and Alcohol Abuse</i> , 2007, 33, 191-206.	2.1	108
108	Sex steroid hormones, stress response, and drug craving in cocaine-dependent women: Implications for relapse susceptibility.. <i>Experimental and Clinical Psychopharmacology</i> , 2007, 15, 445-452.	1.8	107

#	ARTICLE	IF	CITATIONS
109	Progesterone effects on cocaine use in male cocaine users maintained on methadone: A randomized, double-blind, pilot study.. <i>Experimental and Clinical Psychopharmacology</i> , 2007, 15, 453-460.	1.8	31
110	Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. <i>Drug and Alcohol Dependence</i> , 2007, 87, 1-9.	3.2	85
111	Biological Treatments for Amphetamine Dependence. <i>CNS Drugs</i> , 2007, 21, 851-869.	5.9	16
112	Cocaine Withdrawal Symptoms Predict Medication Response in Cocaine Users. <i>American Journal of Drug and Alcohol Abuse</i> , 2006, 32, 617-627.	2.1	24
113	Emerging pharmacological strategies in the fight against cocaine addiction. <i>Expert Opinion on Emerging Drugs</i> , 2006, 11, 91-98.	2.4	91
114	Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers. <i>Behavioural Pharmacology</i> , 2006, 17, 731-735.	1.7	10
115	Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. <i>Psychopharmacology</i> , 2006, 184, 645-651.	3.1	43
116	Six-Month Trial of Bupropion With Contingency Management for Cocaine Dependence in a Methadone-Maintained Population. <i>Archives of General Psychiatry</i> , 2006, 63, 219.	12.3	154
117	GABAergic Agents for the Treatment of Nicotine Dependence. , 2006, , 177-186.		0
118	Tiagabine affects the subjective responses to cocaine in humans. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 82, 569-573.	2.9	18
119	Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. <i>Psychopharmacology</i> , 2005, 181, 504-510.	3.1	38
120	Novel Approaches to the Treatment of Cocaine Addiction. <i>CNS Drugs</i> , 2005, 19, 13-25.	5.9	107
121	The effect of individual cocaine withdrawal symptoms on outcomes in cocaine users. <i>Addictive Behaviors</i> , 2005, 30, 1125-1134.	3.0	40
122	Effects of progesterone treatment on cocaine responses in male and female cocaine users. <i>Pharmacology Biochemistry and Behavior</i> , 2004, 78, 699-705.	2.9	122
123	Pharmacologic management of relapse prevention in addictive disorders. <i>Psychiatric Clinics of North America</i> , 2004, 27, 627-648.	1.3	26
124	Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. <i>Pharmacology Biochemistry and Behavior</i> , 2003, 75, 801-808.	2.9	32
125	Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. <i>Addiction</i> , 2003, 98, 1625-1632.	3.3	119
126	Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine. <i>Drug and Alcohol Dependence</i> , 2003, 69, 273-282.	3.2	57

#	ARTICLE	IF	CITATIONS
127	Prediction of Treatment Outcome by Baseline Urine Cocaine Results and Self-Reported Cocaine Use for Cocaine and Opioid Dependence. <i>American Journal of Drug and Alcohol Abuse</i> , 2003, 29, 713-727.	2.1	54
128	Labetalol treatment enhances the attenuation of tobacco withdrawal symptoms by nicotine in abstinent smokers. <i>Nicotine and Tobacco Research</i> , 2003, 5, 947-953.	2.6	19
129	Effects of progesterone treatment on smoked cocaine response in women. <i>Pharmacology Biochemistry and Behavior</i> , 2002, 72, 431-435.	2.9	124
130	Depressive symptoms modulate the subjective and physiological response to cocaine in humans. <i>Drug and Alcohol Dependence</i> , 2001, 63, 131-137.	3.2	38
131	Progesterone treatment during the early follicular phase of the menstrual cycle: Effects on smoking behavior in women. <i>Pharmacology Biochemistry and Behavior</i> , 2001, 69, 299-304.	2.9	87
132	Individual Differences in the Subjective Response to Smoked Cocaine in Humans. <i>American Journal of Drug and Alcohol Abuse</i> , 2000, 26, 591-602.	2.1	18
133	Effects of Labetalol Treatment on the Physiological and Subjective Response to Smoked Cocaine. <i>Pharmacology Biochemistry and Behavior</i> , 2000, 65, 255-259.	2.9	52
134	Carvedilol affects the physiological and behavioral response to smoked cocaine in humans. <i>Drug and Alcohol Dependence</i> , 2000, 60, 69-76.	3.2	59
135	Effects of phenytoin on cocaine self-administration in humans1Portions of this report were presented at the 59th Annual Scientific Meeting of the College on the Problems of Drug Dependence, Nashville, June 1997.1. <i>Drug and Alcohol Dependence</i> , 1999, 53, 273-275.	3.2	17
136	Sex and menstrual cycle differences in the subjective effects from smoked cocaine in humans.. <i>Experimental and Clinical Psychopharmacology</i> , 1999, 7, 274-283.	1.8	234